Request Call Back

Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Did you experience any of the following side effects?
(Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Risperdal (Risperidone) Linked to Enlarged Breasts (Gynecomastia) in Young Men

Risperdal (Risperidone) Linked to Enlarged Breasts (Gynecomastia) in Young Men

Risperdal (Risperidone) Linked to Enlarged Breasts (Gynecomastia) in Young Men

Risperdal Lawsuits for Gynecomastia (enlargement of breast in men) - J&J Lawsuit

Parker Waichman LLP is investigating potential lawsuits on behalf of young men who developed gynecomastia (enlarged breasts in men) after taking the antipsychotic medication Risperdal. A number of studies have linked the use of Risperdal to enlarged breast tissue in young men and in September 2012, Johnson & Johnson settled the first of over 100 Risperdal gynecomastia lawsuits. If you or someone you know took Risperdal and suffered from gynecomastia, our attorneys would like to speak with you. Call Parker Waichman LLP for a free, no-obligation evaluation of your case.

Risperdal Linked to Gynecomastia

Risperdal is an antipsychotic medication manufactured by Johnson & Johnson; it is used to treat psychiatric disorders such as schizophrenia, bipolar disorder, acute mania associated with autistic disorders and other mental illnesses. However, reports suggest that using Risperdal may lead to breast growth in men, or gynecomastia. Risperdal can cause increased levels of prolactin, which is a hormone that regulates breast growth in milk production; in women this can lead to spontaneous milk production but in men it may cause gynecomastia.

This association between Risperdal and male breast growth was first made public in 1999, when Psychopharmacology journal published a study linking Risperdal to gynecomastia when used with the antidepressant Prozac (fluoxetine). In 2006, the Journal of Clinical Psychopharmacology published a study showing that prolactin levels can increase significantly when Risperdal was given to adolescents. Yet another study, published in the Journal of Child and Adolescent Psychopharmacology in 2009, found that elevated prolactin levels associated with Risperdal use persisted for up to two years.

There are about 130 lawsuits alleging Risperdal caused gynecomastia. The first of these lawsuits was settled in 2012 for an undisclosed amount. The lawsuit was filed on behalf of a young man, who alleged that Risperdal caused breast growth after he used the medication for four years between the ages of nine and 13. Johnson & Johnson settled the case just as the lawsuit was about to go to trial in Pennsylvania state court.

What is Gynecomastia?

Gynecomastia is the enlargement of breast tissue in males. Gynecomastia can affect one or both breasts, sometimes unevenly. Although this condition may not pose any serious health threats, Mayo Clinic states that it can cause psychological or emotional trauma. Men afflicted with gynecomastic may feel pain in their breasts or feel embarrassed about their appearance. Signs of gynecomastia include swollen breast gland tissue and breast tenderness. Mayo Clinic advises patients to visit a doctor if they experience:

  • Swelling
  • Pain
  • Tenderness
  • Nipple discharge in one or both breasts

J&J Ordered to Pay $2.5 Million in First Trial

In February 2015, the first Risperdal lawsuit to go to trial over gynecomastia claims concluded with a $2.5 million verdict in favor of the plaintiff. A Philadelphia jury found that the company failed to warn the plaintiff and physicians about the risks of hormonal imbalance and abnormal breast growth in boys.

The month-long trial took place in Philadelphia County Court of Common Pleas where jurors considered a lawsuit filed on behalf of a boy who developed large breasts after taking Risperdal to treat behaviors associated with autism. He started taking the drug in 2002, at the age of seven, and continued treatment with Risperdal for five years. The suit alleged that, for years, Janssen worked to hide evidence that Risperdal could cause the growth of female breast tissue in adolescent boys.

Former FDA commissioner David Kessler testified in the trial. He said he believed that J&J intentionally manipulated data to minimize gynecomastia risks associated with Risperdal.

The FDA only approved Risperdal for use in adults at the time when the plaintiff began taking the drug. At that time, it was alleged that Janssen sales representatives visited the plaintiff's pediatric neurologist to distribute Risperdal samples several times between 2002 and 2004.

Before the early 2000s, roughly 20 percent of Risperdal prescriptions were written for children and adolescents. In 2006, Risperdal was approved to treat behavioral disorders in children with autism. At this time, the label was updated to state that gynecomastia occurred in 2.3 percent of pediatric patients. The previous label represented the condition as rare.

Legal Help for Victims of Risperdal Side Effects

If you or a loved one took Risperdal and suffered from gynecomastia or other potential side effects, you may have valuable legal rights. Please fill out our online for or call 1-800-YOURLAWYER (1-800-968-7529) to speak with one of our experienced drug injury attorneys today.



Risperdal (Risperidone) Linked to Enlarged Breasts (Gynecomastia) in Young MenRSS Feed

Makers of Risperdal Manipulated Data on Gynecomastia

Oct 17, 2016
Makers of Risperdal is Responsible for Gnecomatia After a $70 million verdict in a Risperdal gynecomastia lawsuit in July, Janssen Pharmaceuticals and its parent company Johnson & Johnson may be re-examining their strategy for pending Risperdal lawsuits. The lawsuits allege that the Risperdal is responsible for gynecomastia-the growth of female breasts-in boys and teenage males who take the drug. The Food and Drug Administration (FDA) originally approved Risperdal (risperidone) for...

Philadelphia Jury Returns $70 Million Verdict in Risperdal Gynecomastia Trial

Jul 5, 2016
In the largest award yet made in a Risperdal gynecomastia trial, last week a Philadelphia jury awarded $70 million to a Tennessee boy who developed female breasts (gynecomastia) after taking the antipsychotic drug Risperdal. This case was the fifth Risperdal gynecomastia case to be tried in Philadelphia, and this verdict is many times larger than previous awards: in three of four earlier cases, verdicts ranged from $500,000 to $2.2 million, reports. During the trial, lawyers for...

Risperdal Gynecomastia Lawsuit Judge Upholds Jury's Decision

Jun 13, 2016
In an appeal filed in a lawsuit involving the connection between the psychiatric drug Risperdal and male breast growth known as gynecomastia, the Pennsylvania Superior Court will soon be deciding whether punitive damages will be allowed in similar cases. Documents filed in this lawsuit say that the plaintiff had been prescribed Risperdal from 2006 to 2009 to help treat his symptoms of Tourette's syndrome. He alleged his gynecomastia developed as a result of that treatment, reports Top Class...

Johnson & Johnson to Pay $1.75 Million in Risperdal Lawsuit

May 10, 2016
A Philadelphia jury awarded a young man $1.75 million in a suit concerning the prescription drug Risperdal. The plaintiff started taking Risperdal at the age of 9 in 2003. At that time, Risperdal had been approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of schizophrenia in adults. It was not until five years later that Risperdal was approved for the use of children and adolescents. During that time, the plaintiff developed gynecomastia, an abnormal growth of...

Risperdal Trial Paused as Janssen Ordered to Turn Over More Evidence

Nov 20, 2015
A trial in Philadelphia state court over breast growth in an adolescent boy allegedly caused by the antipsychotic drug Risperdal (risperidone), has been paused until early December so the company can turn over more evidence for the boy's attorneys to review. Judge Kenneth Powell of the Philadelphia Court of Common Pleas ordered Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, to provide evidence, documents, reports and other nonprivileged information relating to "reanalysis data"...

More Risperdal (Risperidone) Linked to Enlarged Breasts (Gynecomastia) in Young Men News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo